SEC Form 4 · accession 0001306541-18-000004
KYTO BIOPHARMA INC · KBPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Apr 25, 2018
Accepted (ET)
Jun 7, 2018 · 2:26 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001164888
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class B Preferred SharesF1 | Apr 25, 2018 | J | 400,000 | $0.80 | A | 400,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| WarrantF1 | $1.20 | Apr 25, 2018 | J | 400,000 | A | Apr 25, 2018 | Apr 25, 2021 | Common | 333,333 | 400,000 | D |
Explanation of responses
- F1Conversion of debt totalling $320,000 owed by Issuer to Reporting Company - Comindus Finance Corp. - into 400,000 Preferred Units at $0.80 per Unit - each Unit consisting of 1 Class B Preferred Share and 1 Warrant exercisable into 1 common share at $1.20 to 25/04/2021